Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
Carmen M. Labandeira,Maria G. Alonso Losada,Rosa Yáñez Baña,Maria Icíar Cimas Hernando,Iria Cabo López,Jose Manuel Paz González,Maria José Gonzalez Palmás,Cristina Martínez Miró,Diego Santos García +8 more
TLDR
The SAFINON MOTOR study as mentioned in this paper showed that SAFINamide improves mood in patients with Parkinson's disease at 6 months by reducing the BDI-II (Beck Depression Inventory-II), NMSS mood/apathy domain, and PDQ-39 (Parkinson’s Disease Questionnaire-39) emotional well-being domain.Abstract:
Mood disorders are frequent in Parkinson’s disease (PD) and a favorable effect of safinamide on mood has been observed. We aimed to analyze the effectiveness of safinamide on mood as a secondary objective from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR symptoms in patients with Parkinson’s disease) study. SAFINONMOTOR is a prospective open-label single-arm study conducted in five centers from Spain. Patients with PD were required to have at baseline a Non-Motor Symptoms Scale (NMSS) total score of at least 40. In this analysis, the changes from V1 (baseline) to V4 (6 months ± 1 month) in the BDI-II (Beck Depression Inventory-II), NMSS mood/apathy domain, and PDQ-39 (Parkinson’s Disease Questionnaire-39) emotional well‐being domain were analyzed. Depression was identified and classified (DSM-IV and Judd criteria) at baseline and at the end of follow-up as major depression (MD), minor depression (mD), subthreshold depression (subD), and non-depression (nonD). Fifty patients with PD were included (age 68.5 ± 9.12 years; 58% women; 6.4 ± 5.1 years from diagnosis) and 44 patients (88%) completed the follow-up at 6 months. The BDI-II total score was reduced by 35.9% (from 15.88 ± 10.46 at V1 to 10.18 ± 6.76 at V4; p < 0.0001). A significant decrease in the NMSS mood/apathy domain and PDQ-39 emotional well‐being domain was observed as well (p < 0.0001). At baseline, 52% of the patients presented MD, 34% mD, 12% subD, and 2% nonD whereas at V4 the percentages were 31.8%, 34.1%, 22.7%, and 11.4%, respectively (p = 0.029). Safinamide improves mood in patients with PD at 6 months.read more
Citations
More filters
Journal ArticleDOI
Safinamide
Carla Caccia,R Maj,M Calabresi,Silvia Maestroni,Laura Faravelli,L. Curatolo,Patricia Salvati,Ruggero Fariello +7 more
TL;DR: Savinamide may be used in PD to reduce l-dopa dosage and also represents a valuable therapeutic drug to test disease-modifying potential.
Journal ArticleDOI
A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
TL;DR: The MAO-B inhibitors have gained considerable status in the therapy of the Parkinson's disease as discussed by the authors since the 1980s and have been used in both mono-and combination therapies.
Journal ArticleDOI
Overcoming undesirable hERG affinity by incorporating fluorine atoms: A case of MAO-B inhibitors derived from 1 H-pyrrolo-[3,2-c]quinolines.
Katarzyna Grychowska,Agnieszka Olejarz-Maciej,Klaudia Blicharz,Wojciech Pietruś,Tadeusz Karcz,Rafał Kurczab,Paulina Koczurkiewicz,Agata Doroz-Płonka,Gniewomir Latacz,Abdul Raheem Keeri,Kamil Piska,Grzegorz Satała,Joanna Pęgiel,Wojciech Trybała,Magdalena Jastrzębska-Więsek,Andrzej J. Bojarski,Frédéric Lamaty,Anna Partyka,Maria Walczak,Martyna Krawczyk,Natalia Malikowska-Racia,Piotr Popik,Paweł Zajdel +22 more
TL;DR: In this paper , a group of 1H-pyrrolo[3,2-c]quinolines that are capable of inhibiting monoamine oxidase type B (MAO-B) was proposed.
Journal ArticleDOI
Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study
Claudia De Masi,Claudio Liguori,Matteo Spanetta,Mariana Fernandes,Rocco Cerroni,Elena Garasto,Mariangela Pierantozzi,Nicola Biagio Mercuri,Alessandro Stefani +8 more
TL;DR: In this article , the effect of safinamide treatment on non-motor symptoms (NMS) and quality of life in motor-fluctuating PD patients was explored through validated sales.
Journal ArticleDOI
Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
Caterina Pauletti,Nicoletta Locuratolo,Daniela Mannarelli,A Maffucci,Alessia Petritis,Francesco Fattapposta +5 more
TL;DR: In this paper , the authors used the validated versions of fatigue severity scale (FSS) and Parkinson fatigue scale-16 (PFS-16) to test the hypothesis that safinamide could represent an effective treatment of fatigue in Parkinson's disease patients, given its dual mechanism of action.
References
More filters
Journal ArticleDOI
A systematic review of prevalence studies of dementia in Parkinson's disease.
TL;DR: A systematic review of previous studies of the prevalence of PDD using PubMed to search the literature suggests that 24 to 31% of PD patients have dementia, and that 3 to 4% of the dementia in the population would be due to PDD.
Journal ArticleDOI
A systematic review of prevalence studies of depression in Parkinson's disease: The Prevalence of Depression in PD
TL;DR: It is suggested that the average prevalence of major depressive disorder in PD is substantial, but lower than generally assumed.
Journal ArticleDOI
Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
Bruno Dubois,David J. Burn,Christopher G. Goetz,Dag Aarsland,Dag Aarsland,Richard G. Brown,Gerald A. Broe,Dennis W. Dickson,Charles Duyckaerts,J. L. Cummings,Serge Gauthier,Amos D. Korczyn,Andrew J. Lees,Richard Levy,Irene Litvan,Yoshikuni Mizuno,Ian G. McKeith,C. Warren Olanow,Werner Poewe,Cristina Sampaio,Eduardo Tolosa,Murat Emre +21 more
TL;DR: The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment.
Journal ArticleDOI
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Moussa B.H. Youdim,Y S Bakhle +1 more
TL;DR: The concept of neuroprotection, reflecting the possibility of slowing, halting and maybe reversing, neurodegeneration in Parkinson's or Alzheimer's diseases, and selective inhibition of brain MAO could contribute importantly to lowering such stress are suggested.
Related Papers (5)
Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression.
Diego Santos-García,T de Deus Fonticoba,E Suárez Castro,Aaron Diaz,C Cores Bartolomé,M J Feal Panceiras,J M Paz González,L Valdés Aymerich,J M García Moreno,M. Blázquez Estrada,Silvia Jesús,P. Mir,Miquel Aguilar,Lluís Planellas,J García Caldentey,Nuria Caballol,I. Legarda,I Cabo López,L. López Manzanares,M A Ávila Rivera,M J Catalán,L.M. López Díaz,C Borrué,M Álvarez Sauco,Lydia Vela,Esther Cubo,J.C. Martínez Castrillo,P Sánchez Alonso,M G Alonso Losada,N López Ariztegui,I Gastón,Berta Pascual-Sedano,M Seijo,J Ruíz Martínez,C Valero,Monica M. Kurtis,J González Ardura,C Prieto Jurczynska,Pablo Martinez-Martin +38 more